Bionano Genomics Financial Statements (BNGO)
|
|
|
|
Report date
|
|
|
01.03.2022 |
09.03.2023 |
05.03.2024 |
31.03.2025 |
23.03.2026 |
|
23.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
18.0 |
27.8 |
36.1 |
30.8 |
28.5 |
|
28.5 |
|
Operating Income, bln rub |
|
|
-77.1 |
-131.7 |
-215.2 |
-104.0 |
-33.3 |
|
-33.3 |
|
EBITDA, bln rub |
? |
|
-73.9 |
-120.3 |
-213.6 |
-97.5 |
-23.6 |
|
-23.6 |
|
Net profit, bln rub |
? |
|
-72.4 |
-132.6 |
-232.5 |
-112.0 |
-26.4 |
|
-26.4 |
|
|
OCF, bln rub |
? |
|
-71.9 |
-124.8 |
-125.2 |
-68.9 |
-16.3 |
|
-16.3 |
|
CAPEX, bln rub |
? |
|
1.46 |
3.30 |
1.69 |
0.103 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-73.4 |
-128.1 |
-126.9 |
-69.0 |
-16.3 |
|
-16.3 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
81.0 |
137.6 |
224.8 |
104.4 |
39.6 |
|
39.6 |
|
Cost of production, bln rub |
|
|
14.1 |
21.9 |
26.6 |
30.4 |
22.3 |
|
22.3 |
|
R&D, bln rub |
|
|
22.5 |
49.0 |
54.0 |
24.8 |
11.4 |
|
11.4 |
|
Interest expenses, bln rub |
|
|
0.927 |
0.298 |
5.12 |
0.289 |
0.298 |
|
0.230 |
|
|
Assets, bln rub |
|
|
377.1 |
307.5 |
214.4 |
76.7 |
73.6 |
|
73.6 |
|
Net Assets, bln rub |
? |
|
337.1 |
249.4 |
96.2 |
35.4 |
44.4 |
|
44.4 |
|
Debt, bln rub |
|
|
10.7 |
11.7 |
79.4 |
27.3 |
6.92 |
|
6.92 |
|
Cash, bln rub |
|
|
250.6 |
113.2 |
66.8 |
9.48 |
13.3 |
|
13.3 |
|
Net debt, bln rub |
|
|
-239.9 |
-101.5 |
12.6 |
17.8 |
-6.34 |
|
-6.34 |
|
|
Ordinary share price, rub |
|
|
1 794 |
14.6 |
1.89 |
17.3 |
1.53 |
|
1.47 |
|
Number of ordinary shares, mln |
|
|
0.471 |
0.492 |
0.580 |
1.90 |
5.45 |
|
5.45 |
|
|
Market cap, bln rub |
|
|
844 |
7 |
1 |
33 |
8 |
|
8 |
|
EV, bln rub |
? |
|
604 |
-94 |
14 |
51 |
2 |
|
2 |
|
Book value, bln rub |
|
|
254 |
131 |
62 |
26 |
40 |
|
40 |
|
|
EPS, rub |
? |
|
-153.9 |
-269.7 |
-400.6 |
-58.9 |
-4.85 |
|
-4.85 |
|
FCF/share, rub |
|
|
-156.0 |
-260.6 |
-218.6 |
-36.3 |
-3.00 |
|
-3.00 |
|
BV/share, rub |
|
|
540.1 |
266.4 |
107.1 |
13.5 |
7.36 |
|
7.36 |
|
|
EBITDA margin, % |
? |
|
-410.7% |
-432.8% |
-591.4% |
-316.7% |
-82.8% |
|
-82.8% |
|
Net margin, % |
? |
|
-402.8% |
-476.9% |
-643.7% |
-364.0% |
-92.6% |
|
-92.6% |
|
FCF yield, % |
? |
|
-8.69% |
-1 785% |
-11 566% |
-209.7% |
-196.2% |
|
-204.2% |
|
ROE, % |
? |
|
-21.5% |
-53.2% |
-241.8% |
-316.7% |
-59.4% |
|
-59.4% |
|
ROA, % |
? |
|
-19.2% |
-43.1% |
-108.4% |
-146.1% |
-35.9% |
|
-35.9% |
|
|
P/E |
? |
|
-11.7 |
-0.05 |
0.00 |
-0.29 |
-0.32 |
|
-0.30 |
|
P/FCF |
|
|
-11.5 |
-0.06 |
-0.01 |
-0.48 |
-0.51 |
|
-0.49 |
|
P/S |
? |
|
46.9 |
0.26 |
0.03 |
1.07 |
0.29 |
|
0.28 |
|
P/BV |
? |
|
3.32 |
0.05 |
0.02 |
1.28 |
0.21 |
|
0.20 |
|
EV/EBITDA |
? |
|
-8.18 |
0.78 |
-0.06 |
-0.52 |
-0.08 |
|
-0.07 |
|
Debt/EBITDA |
|
|
3.25 |
0.84 |
-0.06 |
-0.18 |
0.27 |
|
0.27 |
|
|
R&D/CAPEX, % |
|
|
1 540% |
1 485% |
3 195% |
24 081% |
|
|
|
|
|
CAPEX/Revenue, % |
|
|
8.12% |
11.9% |
4.68% |
0.33% |
0.00% |
|
0 |
|
| Bionano Genomics shareholders |
